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cell-cell transmission supports the domain’s
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Roland R Regoes3 and Alexandra Trkola1*
Abstract
Background: Variable loops 1 and 2 (V1V2) of the HIV-1 envelope glycoprotein gp120 perform two key functions:
ensuring envelope trimer entry competence and shielding against neutralizing antibodies. While preserving entry
functionality would suggest a high need for V1V2 sequence optimization and conservation, shielding efficacy is
known to depend on a high flexibility of V1V2 giving rise to its substantial sequence variability. How entry competence
of the trimer is maintained despite the continuous emergence of antibody escape mutations within V1V2 has not been
resolved. Since HIV cell-cell transmission is considered a highly effective means of virus dissemination, we investigated
whether cell-cell transmission may serve to enhance infectivity of V1V2 variants with debilitated free virus entry.
Results: In a detailed comparison of wt and V1V2 mutant envelopes, V1V2 proved to be a key factor in ascertaining
free virus infectivity, with V1V2 mutants displaying significantly reduced trimer integrity. Despite these defects, cell-cell
transmission was able to partially rescue infectivity of V1V2 mutant viruses. We identified two regions, encompassing
amino acids 156 to 160 (targeted by broadly neutralizing antibodies) and 175 to 180 (encompassing the α4β7 binding
site) which were particularly prone to free virus infectivity loss upon mutation but maintained infectivity in cell-cell
transmission. Of note, V1V2 antibody shielding proved important during both free virus infection and cell-cell
transmission.
Conclusions: Based on our data we propose a model for V1V2 evolution that centers on cell-cell transmission as a
salvage pathway for virus replication. Escape from antibody neutralization may frequently result in V1V2 mutations
that reduce free virus infectivity. Cell-cell transmission could provide these escape viruses with sufficiently high
replication levels that enable selection of compensatory mutations, thereby restoring free virus infectivity while
ensuring antibody escape. Thus, our study highlights the need to factor in cell-cell transmission when considering
neutralization escape pathways of HIV-1.
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Background
The HIV-1 envelope trimer, consisting of three gp120 –
gp41 heterodimers, is responsible for mediating HIV
entry into target cells and is the sole target of neutraliz-
ing antibodies elicited in HIV infected individuals [1,2].
The variable loops 1 and 2 (V1V2) of gp120 are a key
component in shaping the envelope’s susceptibility to
neutralization and have long been known to potently
shield the trimer against antibody attack [3-13]. Muta-
tions triggered by antibody escape are regarded as the
driving force of the high intra- and inter-patient se-
quence variation of the V1V2 domain [14,15]. Despite its
seemingly high adaptability, mutations within V1V2 can
impair envelope trimer functionality and integrity as the
domain mediates intra- and inter-gp120 subunit interac-
tions at the apex of the envelope spike [16-18]. Numer-
ous naturally occurring V1V2 mutations as well as
deletion of the entire domain were described to either
obliterate or strongly reduce virus infectivity [3,9,19-25].
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Besides its role for trimer integrity, the V1V2 domain
prevents premature adoption of the CD4-bound trimer
conformation [16-18,26,27]. This is of importance for
preserving a metastable trimer structure that upon recep-
tor binding and structural rearrangements provides the
energy required to complete the entry process [1,28,29].
Secondly, the closed, non-CD4 triggered trimer conform-
ation secures shielding of neutralization-sensitive do-
mains from antibody attack [3-13]. The epitopes profiting
most from V1V2 shielding include the V3 loop, situated
beneath V1V2 in the intact trimer, the CD4 binding site
and CD4-induced epitopes important for co-receptor
binding [3-13]. In summary, the available data show that
disturbance of the quaternary orientation of V1V2 and
V3 at the spike apex, either due to deletion of V1V2 or
mutations within or outside V1V2, result in high in-
creases in neutralization sensitivity to antibodies directed
against these epitopes. In parallel, mutations leading to
V1V2-induced transitions from a closed to an open
trimer configuration result in reductions of virus entry
capacity and trimer stability [3-13,19-25].
Contrasting its role in shielding against neutralizing
antibodies, the V1V2 domain itself is a target of the
neutralization response. Despite the high genetic vari-
ability of V1V2, certain sequence motifs are highly
conserved across strains and are targeted by broadly
neutralizing antibodies (bnAbs) (reviewed in [30]). These
bnAb epitopes, including those of PG9 and PG16, CH01
to CH04, and PGT141 to PGT145, are formed by amino
acid residues in V1V2, glycans originating from V1V2
and, in some cases, parts of V3 [31-34]. The importance
of V1V2 as a potential vaccine target was recently
underscored by the results of the RV144 vaccine trial,
with antibodies directed against V1V2 being the main
correlate of protection [35-38]. However, due to the low
constraints on V1V2 sequence conservation, evidenced by
the high frequency of single point mutations, length poly-
morphisms and changes in glycosylation pattern, escape
to neutralizing antibodies directed against V1V2 or do-
mains shielded by V1V2 develops rapidly [10,24,39-48]. A
better understanding of the escape pathways that allow
V1V2 to steer neutralization sensitivity and their conse-
quences for viral infectivity and transmission is thus
pivotal to support and guide vaccine design.
Here, we describe a detailed analysis of functional
properties of V1V2 during the HIV-1 entry process. Spe-
cifically, we explored whether cell-cell transmission may
be a potential rescue path for viruses with low entry cap-
acity due to alterations in V1V2. Infectivity during cell-
cell transmission has been estimated to be several orders
of magnitude higher than free virus infection [49-54]
and can overcome barriers to free virus infection includ-
ing low target cell infectability, low virus production in
infected cells, or low virus stability [55-57]. Due to its
dual roles of shielding against neutralization and ensur-
ing trimer integrity, resistance evolution of V1V2 is
likely an iterative process that frequently generates virus
variants with decreased replication capacity that require
compensating mutations to thrive. Hence, we hypothe-
sized that if emerging V1V2 mutants retain partial cell-
cell transmission capacity, this would enable the virus to
maintain debilitating resistance mutations while sam-
pling compensatory mutations to restore free virus in-
fectivity. Utilizing cell-cell transmissibility would indeed
be doubly beneficial for the virus as it may not only
boost infectivity but also provide a sheltered environment
largely refractory to antibody neutralization [49,58,59]. As
we show here, cell-cell transmissibility is indeed better
preserved than free virus infectivity among naturally
occurring and engineered V1V2 mutant envelopes. Hence,
cell-cell transmission may constitute an important salvage
pathway for replication of antibody escape variants,
highlighting the need to factor in cell-cell transmission
when considering antibody escape pathways of HIV-1.
Results
Dissecting the influence of the V1V2 domain during
different virus entry pathways
Virions produced by an HIV-infected cell can infect
distant target cells as free virus or transfer directly to a
neighboring cell via formation of a virological synapse,
the canonical cell-cell transmission pathway [49,60]. Dis-
secting the relative contribution of the two entry modes
requires assay formats that shift the entry process to one
pathway while limiting or obliterating the other. As the
aim of our study was to explore differences in V1V2
functionality during HIV-1 free virus infection and cell-
cell transmission, we chose assay formats that (i) distin-
guish between the two entry modes, (ii) allow comparisons
of the respective entry efficacies, and (iii) yield comparable
results across a range of target and donor cells (Additional
file 1). To establish and validate our assay setups we ana-
lyzed a panel of four JR-FL env variants for their cell-cell
transmission and free virus entry capacity. Besides JR-FL
wildtype (wt) we probed the V2 point mutant JR-FL I165P
(that has no impact on free virus infectivity and served as
control) and V2 point mutations L175P [11] and D180N
[61], which were previously described to interfere with env
structural integrity and neutralization sensitivity.
To probe HIV-1 cell-cell transmission we utilized a
recently introduced reporter system [56,62], which is
based on co-transfection of virus producer cells with a
Gaussia Luciferase reporter (inGLuc) together with
plasmids encoding HIV. As described [56,62], an intron
in the GLuc reporter gene and its reversed orientation
in the vector prevents reporter signals from transfected
donor cells or upon donor-target cell fusion (Figure 1A).
Gaussia Luciferase is only produced in target cells upon
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successful infection by viruses that contain the inGLuc
reporter and that entered either as free virus or via
cell-cell transmission (Figure 1A). To monitor genuine
cell-cell transmission we restricted free virus infection
by omitting DEAE dextran in the co-culture medium,
which we previously showed to limit infection of trans-
formed cell lines by free virus but not cell-cell trans-
mission (Figure 1B and [58]). Free virus infectivity was
assessed in parallel using single cycle virus infection
assays. To assure maximal comparability between free
virus infection and cell-cell transmission, we employed
cells transfected with HIV encoding plasmids and the
inGLuc reporter as donor cells in cell-cell transmission
setups and in parallel harvested virus-containing super-
natant from the same batch of donor cells to probe free
virus infection (Additional file 1).
To compare efficacies of free virus infection and
cell-cell transmission one can choose between two virus
input standardizations: at the level of the target cell or at
the level of the donor cell. We chose the latter as we were
interested to explore if virions produced by a donor cell
are more infectious during cell-cell transmission or free
virus infection. A set number of donor cells were used as
input in cell-cell transmission assays and corresponding
aliquots of donor cell culture supernatant containing free
virus was used as free virus input (Additional file 1). We
determined the optimal input of donor cells by titration to
ascertain GLuc signals within the dynamic range of the
assay (Figure 1A). To perform matched comparisons of
free virus and cell-cell infectivities, we harvested both
donor cells and virus supernatant from a 12-well culture
and adjusted both to a total volume of 1 ml, which allowed
us to express cell-cell and free virus input in μl volumes
throughout our further analysis (Figure 1 and Additional
file 1). As an input of 100 μl donor cell suspension (15.000
cells) provided the best dynamic range for assessing cell-
cell transmission (Figure 1A), we used the corresponding
amount of free virus (100 μl) as maximum volume in
titrations for free virus infection (Figure 1B and Additional
file 1).
For direct comparison of infectivities in both transmis-
sion modes culture conditions should be as similar as
possible. We thus assessed both transmission modes in
medium lacking DEAE. When we compared absolute
infectivities of the JR-FL env panel we found that levels
of infection were considerably higher during cell-cell
transmission than during free virus infection (Figure 1B).
Cell-cell transmission of JR-FL wt env was 80-fold more
effective than free virus infection, in agreement with
previous reports [49-51,60,63]. Free virus infectivity of
env mutants L175P and D180N in absence of DEAE was
only marginally above mock infected control and hence
proved too low to ensure accurate detection (Figure 1B).
Since quantitative comparisons of cell-cell transmission
and free virus infection across viruses with different
infectivities under identical culture conditions was
therefore not feasible, we additionally probed free virus
infectivity in presence of DEAE. Although addition of
DEAE improved free virus infectivity of A3.01-CCR5
cells, absolute signals were still comparatively low, with
the GLuc signal for JR-FL wt being only about 10-fold
above the signal from mock-infected cells. In contrast,
Figure 1 Assessing free virus infection and cell-cell transmission
with the inGLuc reporter system. (A) Evaluation of cell-cell
transmission between 293-T donor cells and A301-CCR5 target cells.
The optimal input of 293-T donor cells in co-culture setups with A3.01-
CCR5 target cells was determined by titration of 293-T donor cells
transfected with the indicated JR-FL env variants or mock control (no
env). A3.01-CCR5 target cells were kept constant at 50.000 cells. 100 μl
donor cell input corresponds to approximately 15.000 293-T cells. The
grey box highlights the donor cell input chosen for subsequent assays
(100 μl) since this input best covered a wide range of envelope
infectivities while still being in the dynamic range of the assay. Mean
and SD of two independent experiments with two replicates are
shown. Inset: an input of 100 μl 293-T cells transfected with JR-FL wt
reporter virus was treated with the RT inhibitor Tenofovir or the
protease inhibitor Lopinavir prior to starting the cell-cell co-culture.
Both inhibitors completely abolished target cell infection. (B) Absolute
GLuc reporter signals obtained in cell-cell transmission and different
free virus infection setups were compared. The relative light units
(RLUs) are in all cases normalized to 100 μl infectious input derived
from the same donor cells, either transfected 293-T cells (cell-cell assay)
or free virus stock (free virus assays). As target cells either A3.01-CCR5
cells (50.000 cells for both cell-cell and free virus assays) or TZM-bl cells
(15.000 cells) were used. Mean and SD of two independent experiments
with 2 replicates are shown.
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free virus infectivity on TZM-bl cells in presence of
DEAE yielded high GLuc signals in the range of A3.01-
CCR5 cell-cell transmission, with GLuc signals for
JR-FL wt on TZM-bl cells being 150-fold higher than on
A3.01-CCR5 cells in presence of DEAE (Figure 1B). A
further advantage of the TZM-bl system was its wider
dynamic range (850-fold difference between the signals
of JR-FL wt and mock). Most importantly however, we
observed the same pattern of free virus infectivity for
the different env mutants on both A3.01-CCR5 and
TZM-bl cells. Thus, we had the possibility to assess free
virus infectivity with either target cell line. Regarding
our interest in obtaining precise estimates of free virus
entry capacity of env variants over a wide range of
infectivities, we chose to use TZM-bl cells in presence
of DEAE for assessment of free virus entry due to the
high dynamic range and robust signals obtained in this
assay.
The V1V2 domain differentially influences free virus
infection and cell-cell transmission
Concerning the role of V1V2 in shaping virus transmis-
sion we were specifically interested in addressing two
aspects: i) differences in the efficacy of wt and mutant
viruses within a certain transmission mode, and ii)
comparison of the infectivity patterns between the two
transmission modes. To enable these comparisons we cal-
culated relative infectivities in each assay format (cell-cell
or free virus infection) by normalizing the obtained mutant
env infectivity to the respective wt env (Additional file 2).
The derived relative infectivities (% of wt) were used to
compare if and in which transmission mode env variants
loose or gain activity compared to wt env.
Comparing the relative infectivities of the four JR-FL
env variants shown in Figure 1 revealed that both cell-cell
transmission and free virus infection of the L175P and
D180N mutants was substantially decreased compared
to wt. However, the two mutants maintained significantly
higher infectivity during cell-cell transmission (2.5 and
3.9 fold higher cell-cell transmission than free virus
infectivity of L175P and D180N, respectively; Figure 2A).
To ensure that the results from our cell-cell transmis-
sion assay, which utilizes 293-T cells as donor cells, were
also valid for T-cell to T-cell transmission, we studied
virus transmission between Jurkat (donor) and A3.01-
CCR5 (target) cells (Additional file 1). Since transfection
of Jurkat cells with HIV pseudotyping plasmids yielded
only low levels of virus producing cells (data not shown),
we transfected Jurkat cells with replication competent
(rc) infectious molecular clones carrying JR-FL wt or
mutant envs and the inGLuc vector (rc-TN6inGLuc) and
assessed Jurkat to A3.01-CCR5 cell-cell transmission in
absence of DEAE (Figure 2B and Additional file 1). Jurkat-
derived free virus was probed in parallel for infectivity on
TZM-bl cells in presence of DEAE as described. We
observed the same pattern as with the 293-T donor cells,
with free virus infectivity of the L175P and D180N mu-
tants reduced to levels of 30% and 36% of wt infectivity,
respectively. Cell-cell transmission capacity of the mutant
envs remained at significantly higher levels with 78% and
61% of wt infectivity. This represents 2.6-fold and 1.7-fold
increases in cell-cell transmission capacity over free virus
infectivity for the L175P and D180N mutant, respectively
(Figure 2B). Of note, the relative infectivity of the Jurkat-
derived L175P and D180N mutant rc-TN6inGLuc viruses
on TZM-bl cells as free virus (Figure 2B) was higher com-
pared to the 293-T derived viruses (Figure 2A) (30% versus
9.6% and 36% versus 4.2% for Jurkat and 293-T derived
L175P and D180N virions, respectively), highlighting the
influence of donor and target cells in virus transmission as
previously suggested [56,62,64]. However, the overall
infectivity pattern remained the same: regardless of the
donor cells used, the relative infectivity of cell-cell trans-
mission was higher than infectivity in free virus transmis-
sion (Figure 2A and B). Thus, since 293-T donor cells
yielded results comparable to Jurkat donor cells and add-
itionally offered the possibility to work with env pseudo-
typed viruses, we subsequently utilized the 293-T to
A3.01-CCR5 cell-cell transmission assay for the majority
of analyses.
To obtain further insight on the entry properties of
mutant envs we probed their functionality during cell-
cell-fusion (Figure 2C). Although cell-cell fusion is not a
relevant entry mode leading to productive infection, we
reasoned that assessing fusion may yield important
insights on env functionality, especially for envs that are
strongly impaired in both free virus infection and
cell-cell transmission. Env fusion capacity and free virus
infectivity were determined in parallel using a LTR-GFP
reporter construct. As observed for the inGLuc reporter
viruses, the L175P and D180N mutants were severely
impaired in free virus infectivity (15% and 12% of wt
activity for L175P and D180N, respectively; Figure 2C).
This severe reduction in free virus entry capacity was
not reflected in the fusion capacity of the envs, as
fusogenicity was maintained at comparatively high levels
(60% and 43.5% of wt activity for L175P and D180N,
respectively). Since assessment of fusion capacity thus
provided additional information on entry functionality,
this analysis was included in our further characterization
of env mutants.
V1V2-deleted viruses lose free virus entry capacity but
retain cell-cell transmission and fusion activity
Since the JR-FL V2 mutants L175P and D180N showed
strong reduction in both free virus and cell-cell trans-
mission infectivity we were interested to define the over-
all impact of the V1V2 domain on virus transmission. To
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this end we probed a panel of 10 viruses, encompassing
subtype B Tier-1A viruses (SF162, NL4-3), subtype B Tier-
2 viruses (JR-FL, RHPA, AC10, REJO, ZA110) and subtype
C Tier-2 viruses (CAP88, ZM109, ZM214) to support free
virus infection, cell-cell transmission and cell-cell fusion
as wt and upon V1V2 deletion (Figure 3). While V1V2
deletion will not occur in vivo, the deletion mutants
allowed us to obtain an assessment of the general contribu-
tion of the V1V2 domain to the different entry pathways
across different virus strains as the impact of single point
mutations can differ based on the envelope background
probed.
When we assessed the infectivity of strain ZA110 in
presence and absence of V1V2 in T-cell to T-cell
transmission using Jurkat donor and A3.01-CCR5 target
cells, we found that free virus infectivity of the V1V2-
deleted env was reduced to 32% of wt level (Figure 3A).
In contrast, cell-cell transmission capacity was main-
tained at 65% of wt level, representing a 2-fold higher
efficacy of cell-cell transmission capacity compared to
free virus infection (Figure 3A).
We extended our analyses to the panel of 10 wt and
V1V2-deleted envs and probed them in 293-T to A3.01-
CCR5 cell-cell transmission (Figure 3B). In agreement
with previous reports [3,9,19-25], free virus entry
capacity was strongly reduced upon V1V2 deletion. As
observed for JR-FL V2 point mutants (Figure 1 and 2),
the capacity of V1V2-deleted envs to support cell-cell
Figure 2 JR-FL V2 mutations decrease cell-cell transmission capacity less than free virus infectivity. (A) JR-FL V2 point mutant infectivities
were normalized to JR-FL wt for both free virus infection (black) and cell-cell transmission (red). Values of relative efficacy of cell-cell transmission
versus free virus infection are shown below the bars; a star indicates whether this difference is statistically significant as probed by multiple
unpaired t-tests with alpha = 0.05. Mean and SD from 4 independent experiments performed in duplicates are depicted. (B) Analysis of JR-FL wt
and V2 point mutants in T-cell to T-cell transmission using Jurkat donor cells (expressing replication competent TN6inGLuc reporter viruses) and
A301-CCR5 target cells (orange). Cell-cell transmission activity was compared to free virus infectivity of the same Jurkat derived viruses on TZM-bl
cells (black). Data are normalized to JR-FL wt. Values of relative efficacy of cell-cell transmission versus free virus infection are shown below the
bars; a star indicates whether this difference is statistically significant as probed by multiple unpaired t-tests with alpha = 0.05. Mean and SD from
2 independent experiments performed in duplicates are depicted. (C) Analysis of JR-FL wt and V2 point mutant free virus infectivity (black) and
cell-cell fusion capacity (green). Data are normalized to JR-FL wt. Values of relative efficacy of cell-cell fusion versus free virus infection are shown
below the bars; a star indicates whether this difference is statistically significant as probed by multiple unpaired t-tests with alpha = 0.05. Mean
and SD from 2 independent experiments performed in duplicates are depicted.
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transmission was lower compared to wt envs but gener-
ally exceeded free virus infectivity (Figure 3B). One
exception was NL4-3 ΔV1V2, the only virus in our panel
which proved not to excel free virus infectivity during
cell-cell transmission. The other exceptions were SF162
ΔV1V2 and ZM214 ΔV1V2, which both retained cell-
cell transmission activity at or close to wt level (96% and
83% of wt, respectively). This was especially notable for
ZM214 as this virus, in contrast to SF162, showed mark-
edly decreased infectivity as free virus upon V1V2 dele-
tion. For the Tier-1A env clone SF162 the V1V2 domain
seems to be completely dispensable for both free virus
entry and cell-cell transmission. This is in line with the
presumed open trimer conformation of SF162 in which
the V1V2 does not perform the extent of inter-
protomeric contacts required for shielding [9,20]. In
sum, with the exception of NL4-3, all V1V2-deleted vi-
ruses retained partial cell-cell transmission activity, with
no or comparatively lower loss in activity as seen during
free virus transmission. The observed relative activities
were 1.5 to > 8-fold higher in cell–cell transmission than
in free virus infection (Figure 3B). Since both free virus
infection and cell-cell transmission of V1V2-deleted envs
were strongly reduced compared to wt, we ascertained
Figure 3 Higher tolerance towards loss of V1V2 during cell-cell transmission and cell-cell fusion compared to free virus infection.
(A) Analysis of ZA110 wt and V1V2-deleted virus in T-cell to T-cell transmission using Jurkat donor cells (expressing replication competent TN6inGLuc
reporter viruses) and A301-CCR5 target cells (orange). Cell-cell transmission activity was compared to free virus infectivity of the same Jurkat derived
viruses on TZM-bl cells (black). Data are normalized to ZA110 wt. The relative efficacy of cell-cell transmission versus free virus infection of the V1V2
mutant is shown below the bars. Mean and SD from 2 independent experiments are depicted. (B) A panel of 10 wt and V1V2 deletion mutant
pseudoviruses (env-pvinGLuc) were compared in free virus infection of TZM-bl cells (black) and in cell-cell transmission from 293-T cells to A3.01-CCR5
cells (red). ΔV1V2 env mutant infectivity is normalized to each corresponding wt env. Values of relative efficacy of cell-cell transmission versus free virus
infection are shown below the bars; a star indicates whether this difference is statistically significant as probed by multiple unpaired t-tests with
alpha = 0.05. Mean and SD from 3 independent experiments are depicted. (C) The same env panel as shown in (B) was tested for free virus infection
(black) and cell-cell fusion (green). Strain ZM109 ΔV1V2 was not infectious as free virus on TZM-bl cells (marked by a cross). ΔV1V2 env mutant
infectivity or fusion activity were normalized to each corresponding wt env. Values of relative efficacy of cell-cell fusion versus free virus infection are
shown below the bars; a star indicates whether this difference is statistically significant as probed by multiple unpaired t-tests with alpha = 0.05. Mean
and SD from 3 independent experiments performed in duplicates are depicted.
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that the RLU signals obtained in the respective entry
assays were clearly above background and within the
dynamic range of the assays (Additional file 3).
Interestingly, the capacity of V1V2-deleted envs to
mediate cell-cell fusion remained in most cases intact
(Figure 3C; 40 to 120% of wt fusion activity). Fusogeni-
city and free virus infectivity were not tightly linked in
our panel, as for instance AC10, an envelope with the
lowest free virus infectivity upon V1V2 deletion, retained
fusion activity at almost wild type levels (Additional file
4A). In contrast, the other three viruses with compara-
tively low entry efficacy upon V1V2 deletion (JR-FL,
RHPA and ZM109) all showed reduced fusion capacity
(60.5%, 58% and 51.5% of wt fusogenicity, respectively).
Overall, cell-cell fusion activity was maintained at higher
levels (up to >25-fold relative activity over free virus
infectivity) than cell-cell transmission (Figure 3B and C).
Influences of the V1V2 domain on virion trimer content
and stability
While V1V2-deleted envs were expected to show pro-
nounced defects in free virus entry [3,9,19-25], the high
capacity of these envs to retain cell-cell transmission and
cell-cell fusion activities was surprising. We therefore
sought to dissect functions of V1V2 that are required for
free virus entry but are, at least partially, dispensable
during cell-cell transmission. Since V1V2 is a central
component of the trimer required to maintain its integ-
rity and stability [3,9,19-25], V1V2 deletion could poten-
tially inflict a lower density of functional env trimers on
virions that may cause the observed loss of free virus
infectivity. To investigate potential decreases in env con-
tent we probed whether V1V2 deletion results in lower
env expression on producer cells, decreased env incorp-
oration into virions, or an increased propensity to CD4
induced gp120 shedding from trimers (Figure 4 and
Additional file 5). Expression of V1V2-deleted envs on
transfected 293-T cells was comparable to the corre-
sponding wt envs (80 to >100% of wt; Additional file 5A
and B). Similarly, levels of ΔV1V2 gp120 content of
virions was in the range of wt for 8 of the 10 viruses
probed (>80% of wt content, Additional file 5C). The
strongest decrease was observed for ZM109 ΔV1V2,
which only reached 10% of wt ZM109 gp120 levels and
was not functional in free virus entry (Figure 3C). The
second strain with lower gp120 content on virions was
JR-FL ΔV1V2 which reached only 40% of wt levels. A
more marked difference between wt and ΔV1V2 envs
was apparent in their susceptibility to CD4-induced
gp120 shedding, with V1V2-deleted envs showing a
higher propensity to gp120 dissociation upon CD4 bind-
ing in line with previous reports on the reduced stability
of V1V2 deleted envs [26,27] (Figure 4A). To probe the
physical stability of ΔV1V2 virions in more detail, we
analyzed temperature-induced virus infectivity decay in
two different assays. The half-life of wt and V1V2-
deleted virus stocks was determined by incubating virus
samples at 37°C for up to 80 h and determining infectiv-
ity in regular intervals (Figure 4B and Additional file 6).
A
B
C
Figure 4 V1V2 deletion impacts on trimer stability.
(A) Susceptibility of wt (black) and ΔV1V2 envs (red) to CD4-induced
shedding was probed on env-transfected 293-T cells by flow
cytometry. Percent of gp120 shedding upon incubation of env-
expressing cells with CD4-IgG2 in relation to mock-treated controls
is shown. Bars depict mean and SD of 2 independent experiments.
(B) The half-life of wt and ΔV1V2 env virus stocks was determined
by incubation for up to 80 h with periodic sampling and infectivity
assessment on TZM-bl cells. Data points are means from 2 to 3
independent experiments. (C) Wt and ΔV1V2 virus stocks were
subjected for 5 h to temperature gradient from 25°C to 45°C in 2.5°C
steps followed by infectivity assessment on TZM-bl cells. The
temperatures at which 50% infectivity of each stock remained are
depicted. Data points are means of 2 to 3 independent experiments
performed in duplicates.
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The stability of wt envs proved to vary over a wide
range. The most rapid decay was observed for the
Tier-1A strain NL4-3, the highest stability displayed the
Tier-2 env ZA110 with an half maximal decay time of
24 h. Interestingly, V1V2-deleted viruses displayed
significantly faster decay rates than wt envs (Figure 4B;
paired t test p = 0.0002, mean time to half maximal
decay 16.6 h for wt and 11.8 h for ΔV1V2 envs). We
further performed a temperature escalation treatment of
wt and ΔV1V2 viruses by exposing virus aliquots to a
temperature gradient ranging from 25° to 45°C. When
we compared the temperatures at which virus stocks
had lost 50% of their infectivity, we observed a markedly
higher sensitivity of V1V2-deleted envs to increasing
temperatures (Figure 4C and Additional file 7; paired
t-test p = 0.0002; mean temperature at which 50% infect-
ivity loss occurred 36.9°C and 35.1°C for wt and ΔV1V2
envs, respectively). Infectivity decay rates (Figure 4B)
and temperature sensitivity (Figure 4C) of wt and
ΔV1V2 envs correlated (wt envs: r = 0.825, p = 0.0062;
ΔV1V2 envs: r = 0.734, p = 0.0243; Additional file 8). In
summary, although we observed a range of reactivities
for both wt and ΔV1V2 envs in terms of trimer content
and stability, none of the probed parameters by itself
proved to shape free virus and cell-cell infectivity
(Additional file 4B-G). For instance, although V1V2-
deleted JR-FL, AC10 and RHPA had a comparably low
infectivity as free virus, only JR-FL proved to incorporate
lower envelope densities (Additional file 5C). Despite
this, the JR-FL ΔV1V2 env was among those envs which
were closest to their respective wt in terms of decay
rates and temperature stability (Figure 4B and C).
The V1V2 domain is required for shielding against
antibody neutralization during cell-cell transmission
A key function of V1V2 is shielding of the envelope
trimer against neutralizing antibodies [3-13]. However,
whether shielding by V1V2 is critical for both free virus
infection and cell-cell transmission is currently not
known as previous analyses have focused solely on free
virus infection. Considering that efficacy of neutralizing
antibodies is substantially reduced during cell-cell trans-
mission [49,58,59,64], we thought it prudent to probe
whether V1V2 shielding may be of less importance
in this entry mode. To assess antibody neutralization
during cell-cell transmission we utilized 293-T donor
and A3.01-CCR5 target cells, for free virus neutralization
293-T produced virus stocks and TZM-bl target cells
and for fusion inhibition 293-T donor and TZM-bl
target cells. As shown above (Figure 1), utilizing TZM-bl
target cells for free virus neutralization had the advantage
that also virus stocks with low infectivity that showed only
marginal infectivity of A3.01-CCR5 cells could be probed.
Using JR-FL and a panel of neutralizing Abs we verified
that free virus neutralization yielded identical results on
A3.01-CCR5 and TZM-bl cells (data not shown).
We first investigated sensitivity of strain ZA110 as wt
and upon V1V2 deletion against autologous plasma, the
non-neutralizing CD4bs Ab b6, the moderately neutral-
izing V3-directed Ab 1.79 and the weak neutralizing
CD4i Ab 17b during free virus infection and cell-cell
transmission (Figure 5A). The Tier-2 ZA110 wt virus
was not neutralized by any of the mAbs and only par-
tially by the autologous plasma, irrespective if probed as
free or cell-cell transmitted virus. V1V2 deletion strongly
increased sensitivity of free virus to antibody neutraliza-
tion. Sensitivity to neutralization during cell-cell trans-
mission was also heightened upon V1V2 deletion, but
the magnitude of the effect was lower. Cell–cell trans-
mission of ZA110 ΔV1V2 required 6 to 14-fold higher
antibody concentrations to reach 50% inhibition than
free virus infection (50% inhibitory concentration (IC50)
free virus infection vs. IC50 cell-cell transmission: b6
0.42 μg/ml vs. 2.97 μg/ml; 17b 0.041 μg/ml vs. 0.59 μg/ml;
1.79 0.1 μg/ml vs. 0.67 μg/ml).
When we compared V1V2 shielding of JR-FL during
free virus infection and cell-cell fusion, we observed, in
line with earlier reports [3-13], that free virus inhibition
by V3, CD4bs and CD4i directed Abs was increased in
absence of V1V2 shielding (Figure 5B). In contrast, gp41
directed agents (2F5 and T-20) and the gp120 glycan-
specific Ab 2G12 showed no or only modest changes in
activity against wt and V1V2-deleted viruses. As expected,
cell-cell fusion of JR-FL wt proved resistant to antibodies
while the activity of T-20 was retained. In agreement with
free virus neutralization, V3 Abs showed highly improved
activity in blocking cell-cell fusion in absence of V1V2.
Surprisingly, this was not the case for CD4bs Ab b6 and
CD4i Ab 17b, for which V1V2 deletion led to only small
increases in neutralization sensitivity. This suggests that
under conditions of rapid receptor engagement these weak
or non-neutralizing Abs remain less active irrespective of
V1V2 shielding.
We next compared plasma antibody activity of 19 indi-
viduals chronically infected with HIV-1 of subtypes A, B,
C, AE and AG in blocking free virus infection, cell-cell
transmission and cell fusion of strains SF162, NL4-3 and
JR-FL wt and ΔV1V2 (Figure 5C). Free virus inhibition
showed the previously described pattern, with plasma
samples having considerable activity against the Tier-1A
viruses SF162 and NL4-3 but only low activity against
the Tier-2 virus JR-FL (SF162: inhibited by 19 samples at
reciprocal 50% neutralization titers (NT50) up to 105;
NL4-3: inhibited by 17 samples at NT50 up to 104; JR-
FL: inhibited by 10 samples at NT50 up to 103). V1V2
deletion increased neutralization activity against SF162
and JR-FL free virus (NT50 up to 106) in line with im-
proved exposure of V3, CD4bs and CD4i epitopes.
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Figure 5 V1V2 neutralization shielding during cell-cell transmission. (A) to (C): Neutralization activity of mAbs and patient plasma was
evaluated in i) free virus infection by infection of env-pvNLLuc viruses on TZM-bl cells; ii) during cell-cell fusion by co-culture of 293-T cells expressing
env-pvNLGFP and TZM-bl target cells; and iii) during cell-cell transmission by co-culture of 293-T cells expressing env-pvinGLuc and A3.01-CCR5 target cells.
(A) Neutralization sensitivity of isolate ZA110 wt (black squares) and ZA110 ΔV1V2 (red circles) to monoclonal antibodies b6, 17b and 1.79 and to
autologous patient plasma was probed during free virus infection (top row) and cell-cell transmission (bottom row). Data points depict % neutralization
compared to virus infection in absence of inhibitors. Mean and SD from 2 independent experiments performed in duplicate are shown. (B) Inhibition
of JR-FL wt (black squares) and JR-FL ΔV1V2 (red circles) in free virus infection (open symbols) and cell-cell fusion (filled symbols) by mAbs and the
fusion inhibitor T-20. Fifty percent inhibitory concentrations (IC50) in μg/ml calculated from pooled inhibition data derived from 2 to 3 independent
experiments performed in duplicate are shown. (C) Neutralization activity of plasma from 19 individuals with chronic HIV-1 infection (subtypes A, B, C,
AE, AG) against wt and ΔV1V2 mutant viruses of JR-FL, SF162 and NL4-3 was probed in free virus infection (left panel), cell-cell transmission (middle
panel) and cell-cell fusion (right panel). The 50% neutralization titer (NT50, i.e. the reciprocal plasma dilution yielding 50% neutralization) is depicted.
Neutralization titers were derived from 1 to 2 independent experiments, performed in duplicates.
Brandenberg et al. Retrovirology 2014, 11:75 Page 9 of 22
http://www.retrovirology.com/content/11/1/75
Increase in neutralization sensitivity of NL4-3 upon loss
of V1V2 was limited as plasma antibodies to V3 only
rarely cross react with the V3 loop of this X4 user [13].
In contrast to free virus inhibition, none of the 19
plasma samples was capable of blocking cell-cell fusion
of wt virus and only a fraction of the samples had
activity against V1V2-deleted viruses, highlighting that
cell-cell fusion is less prone to antibody attack even in
absence of V1V2 shielding (SF162 ΔV1V2: inhibited by
6 samples; NL4-3 ΔV1V2: inhibited by 5 samples; JR-FL
ΔV1V2: inhibited by 11 samples, all at NT50 below 104).
While wt viruses were equally insensitive to plasma
inhibition during cell-cell transmission, cell-cell trans-
mitted viruses lacking V1V2 portrayed an intermediate
sensitivity with plasma neutralization potency ranging
between free virus neutralization and cell fusion
neutralization titers (SF162 ΔV1V2: inhibited by 15 sam-
ples at NT50 below 105; NL4-3 ΔV1V2: inhibited by 7
samples at NT50 below 103; JR-FL ΔV1V2: inhibited by
15 samples at NT50 below 105). In summary, these data
confirm that in cell-cell transmission, similar to free virus
infection, intact V1V2 shielding is important for the
virus to evade plasma antibody neutralization. However,
the consequences upon loss of shielding by V1V2 are
less pronounced during cell-cell transmission where
neutralization titers were up to 3 orders of magnitude
lower than in free virus transmission. Hence, imperfectly
shielded viruses are highly likely to benefit from replicat-
ing in a cell-cell transmission environment.
Selected V1V2 point mutations differentially affect
free-virus infection and cell-cell transmissibility
While V1V2 deletion mutants served as important tool
to dissect the role of V1V2 in the different entry path-
ways, we thought it prudent to verify the potential
in vivo relevance of the observed effects in the context
of naturally occurring V1V2 mutations. To investigate
which positions in V1V2 are critical to preserve free
virus infectivity we compared free virus infection, cell-
cell transmission and cell-cell fusion capacity of a panel
of 24 JR-CSF envs containing mutations of selected resi-
dues in V1V2 to alanine [65]. The panel includes residues
forming epitopes of previously described V1V2-dependent
antibodies [66,67] and/or being part of potential N-linked
glycosylation sites shown to be critical for virus infectivity.
When we tested the panel in free virus infection and
cell-cell transmission we observed strong decreases in free
virus infectivity for several of the mutants (Figure 6). Al-
though cell-cell transmission capacity of several mutants
was also reduced, infectivity was maintained at higher
levels than in free virus infection. The difference was most
pronounced for mutants that had the highest impact on
free virus infection, including residues 156, 158, 159, 160,
177 and 180. Eight mutants retained free virus infectivity
close to wt level (>90%) or even excelled it. While in all
these cases cell-cell transmission was equally high, the
I165A mutant was unique, as it was the only mutant that
lost cell-cell transmission activity while maintaining high
free virus infectivity. Although cell-cell transmission lead
to a lower loss in infectivity across all mutants, free virus
infectivity and cell-cell transmission capacity were corre-
lated (r = 0.57, p = 0.0036, Additional file 9A) indicating
that functional properties of the envs exist that govern
both transmission modes. This functional link between
free virus and cell-cell transmission for the majority of
envs was even more evident when envs with high cell-cell
transmission capacity and low free virus infectivity (N156A,
F159A and Y177A) and the I165A mutant (showing the
reverse phenotype), were excluded prior to correlation
analysis (r = 0.87, p < 0.0001, Additional file 9B). The cell-
cell fusion capacity of the env panel showed a similar
pattern with fusion capacity being maintained at much
higher rates than free virus infectivity. Fourteen viruses
reached ≥ 75% of wt fusion levels and only 4 viruses
showed fusion activities below 50% of wt fusion capacity
(Additional file 9C).
In a next step we focused our analyses on V1V2 resi-
due 160 which is a crucial component of the epitope of
a class of V1V2-directed broadly neutralizing antibodies
represented by PG9 and PG16 [31]. Escape from these
antibodies is associated with loss of asparagine at pos-
ition 160 (N160) which is conserved in more than 90%
of HIV-1 sequences deposited in the Los Alamos HIV
sequence database (3719 env sequences included; [68]).
PG9/PG16 resistant strains frequently carry a lysine at
position 160 (K160). K160 is found in 2.4% of env
sequences in the Los Alamos database. Among viruses
probed in our study, 3 envs (SF162, CAP88 and ZM214)
encode lysine at position 160. To test the effect on the
entry phenotype of this residue, we generated a panel of
mutant N160K or K160N viruses and analyzed their free
virus infection and cell-cell transmission capacity. In
agreement with previous studies [69], the effect of N160K
on free virus entry ranged from a 10 to 90% loss of entry
capacity for the different isolates tested (Figure 7). Not-
ably, in two of the three strains which naturally contain a
lysine at position 160, SF162 and CAP88, the K160N
mutation reconstituted a potential N-linked glycosylation
site and led to a high increase in free virus infectivity,
highlighting the importance of this residue for free virus
infectivity. In contrast, for strain ZM214 we did not ob-
serve a boost in infectivity upon introduction of K160N.
Interestingly though, in ZM214 the K160N mutation does
not restore an N-x-S/T motif, suggesting that glycosylation
at position 160 is required for the observed boost in free
virus infectivity. When we tested the panel of N160K mu-
tants in cell-cell transmission (Figure 7) the overall picture
was more diverse, indicating that presence or absence of
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the glycosylation site at position 160 has strain-dependent
effects on free virus infectivity and cell-cell transmission
capacity. Out of the 8 probed mutants, 3 envs had identi-
cal or only moderately increased (<10% difference) activity
in cell-cell transmission compared to free virus transmis-
sion. The remaining 5 viruses showed a higher efficacy of
cell-cell transmission (ranging from a 15 to 40% increase
in efficacy compared to free virus infection). SF162 and
CAP88 K160N mutant cell-cell transmission efficacy was
either equal to wt (SF162) or in the range of free virus
transmission (CAP88), but did not excel it, suggesting that
glycosylation at position 160 has a greater effect on free
virus infectivity than on cell-cell transmission. Cell-cell
fusion capacity of the mutants was in all cases maintained
at high levels (65 to 100% of wt; Additional file 10).
Infectivity differences between SF162 and P3N are
steered by V1V2 and N160
The differences in entry efficacy we observed for V1V2
point mutants, in particular N160 variants, were intri-
guing. To obtain further insights into the interplay of
V1V2 variability and infectivity we utilized the Tier-1A
strain SF162 and its Tier-3 derivative P3N, which was
derived from in vivo evolution via successive transfer of
virus in rhesus macaques following initial infection with
SHIV-SF162 [70]. Of particular interest for our study,
strain P3N has substantial amino acid changes compared
to SF162 in V1V2 (Additional file 11), including a switch
from the lysine found at position 160 in SF162 to
Figure 6 Point mutations in V1V2 reduce free virus infectivity stronger than cell-cell transmission capacity. A panel of JR-CSF V1V2 point
mutations was compared for entry efficacy in free virus infection (black) and cell-cell transmission (red). Env mutant infectivities were normalized
to JR-CSF wt and are ranked (left to right) in order of increasing free virus infectivity. Values of relative efficacy of each mutant in cell-cell transmission
over free virus infection are indicated below the bars; stars depict whether this difference reached statistical significance as probed by multiple unpaired
t-tests with alpha = 0.05. Data shown are means and SD from 3 independent experiments performed in duplicates.
Figure 7 The effect of residue N160 on free virus infection and
cell-cell transmission. Eight viruses encoding N160 and 3 viruses
encoding K160 were probed as wt and upon N160K or K160N
mutation in free virus infection (black) and cell-cell transmission
(red). Mutant env infectivity in the two transmission pathways is
normalized to the matching wt env. Values of relative efficacy of
each mutant in cell-cell transmission over free virus infection are
indicated below the bars; stars depict whether this difference
reached statistical significance as probed by multiple unpaired t-tests
with alpha = 0.05. Data shown are means and SD from 2 to 3
independent experiments performed in duplicates.
Brandenberg et al. Retrovirology 2014, 11:75 Page 11 of 22
http://www.retrovirology.com/content/11/1/75
asparagine restoring an N-linked glycosylation motif.
We therefore analyzed the effect of switching between
lysine and asparagine in the parental SF162 and P3N
envelopes. In addition we generated a V1V2-deleted ver-
sion of P3N, as well as swaps of the V1V2 loops between
SF162 and P3N. The panel of wt SF162 and P3N and
their derivatives containing domain swaps and/or muta-
tions of position 160 were analyzed for free virus infect-
ivity, cell-cell transmission and cell-cell fusion activity
(Figure 8A and B). P3N is highly infectious compared to
SF162; however when V1V2 was deleted or replaced
with the V1V2 of SF162, the infectivity of P3N dropped
to a similar level as SF162, highlighting the importance
of V1V2 for the high infectivity of P3N. The opposite
effect was less pronounced, as the V1V2 of P3N inserted
into SF162 lead to only an approximately 2-fold increase
in free virus infectivity, indicating that additional muta-
tions outside V1V2 are required to restore the full
infection potential seen for P3N. The N160K mutation
in P3N had a negligible impact on infectivity, suggesting
that inter-protomeric contacts of P3N are highly opti-
mized and do not depend on a single interaction by
N160. In striking contrast, the infectivity of P3N carry-
ing the V1V2 of SF162 could be restored by introduction
of N160, highlighting the importance of the N160 glycan
for protomer interactions of certain V1V2 domains.
When we tested the env panel for cell-cell transmission
we observed a similar trend, with SF162-derived mutants
remaining close to SF162 wt levels. Notably, P3N wt was
approximately 3-fold better than SF162 wt in cell-cell
transmission, but more than 7-fold better in free virus
infection (Figure 8A). This further underscores that envs
less fit in free virus infection benefit more from cell-cell
transmission, while the advantage of free virus entry com-
petent envs is less pronounced in this entry pathway. Simi-
lar to free virus infection, the loss in cell-cell transmission
capacity observed for the P3N chimera carrying the SF162
V1V2 could be restored by introduction of K160N con-
firming the importance of this residue in both entry
modes. Cell-cell fusion capacity of all envs ranged from
100% to 250% of SF162 wt activity (Figure 8B).
SF162 and SF162 ΔV1V2 are highly neutralization sensi-
tive viruses (Tier-1A), whereas P3N is highly neutraliza-
tion resistant (Tier-3). When V1V2 was deleted from
P3N, it showed a neutralization phenotype as SF162
ΔV1V2 and was potently neutralized by the V3 specific
Ab 1.79 and the CD4bs Ab b6 (Figure 8C). Similarly,
replacement of the P3N V1V2 with that of SF162 lead to a
neutralization-sensitive phenotype comparable to SF162
wt. In contrast, the V1V2 of P3N introduced neutraliza-
tion resistance comparable to P3N wt in SF162. Of note,
the K160N mutation in both SF162 and P3N.V1V2SF162
resulted in a high increase in neutralization resistance.
Thus V1V2, and especially the residue at position 160,
is important for maintaining a closed, neutralization-
resistant and entry-competent trimer conformation. Prob-
ing the association between sensitivity to mAbs 1.79 and
b6 and free virus infectivity of the eight viruses confirmed
this relationship (correlation analysis: b6 r = 0.809, p =
0.015; 1.79 r = 0.775, p = 0.0238; Additional file 12). To
further determine the influence of V1V2 on entry charac-
teristics, we analyzed the SF162 and P3N wt and V1V2-
deleted envs for trimer stability. Analysis of temperature
stability indicated that P3N was the most stable env out of
the four envs tested (Figure 8D and E), providing further
evidence that trimer stability is tightly linked with entry
competence and neutralization resistance.
Discussion
The V1V2 domain of gp120 is a key regulator of virus
infectivity and shielding against neutralizing antibody
attack [3-13,19-25]. Rapid antibody escape mediated by
mutations in V1V2 highlights the latter activity and is
considered the main driver of the high sequence diversity
of the domain [14,15]. How the domain supports this high
plasticity without jeopardizing entry functionality of the
envelope trimer, for which it contributes essential, stabiliz-
ing intra- and inter-protomeric contacts [17,18] has not
been conclusively resolved. We hypothesized that preserv-
ing entry capacity in the face of continuously evolving
neutralization escape mutations will require means for the
virus to quickly adopt compensatory mutations which
rescue infectivity. A prerequisite for this would be that the
escape mutants that arise maintain residual entry capacity.
We reasoned that cell-cell transmission, being a more effi-
cient mode of virus dissemination than free virus infection
[49-57], may play an important role in this context. Since
effects of V1V2 variability on cell-cell transmission efficacy
have not been assessed to date, we set out in this study to
systematically delineate factors that shape entry efficacy of
V1V2 variants during free virus infection and cell-cell
transmission.
When we tested a panel of 10 HIV-1 envs as wt and
upon V1V2 deletion, we observed a strong reduction of
free virus entry efficiency of V1V2 deleted viruses while
their cell-cell transmission and cell-cell fusion capacity
was maintained at considerably higher levels (Figure 3).
To investigate V1V2 functions that shape entry efficacy
we analyzed virion gp120 content, trimer stability and
neutralization phenotype (Figures 4 and 5). Expression
and virion incorporation levels of wt and V1V2-deleted
envs were, with few exceptions, in a comparable range
(Additional file 5). However, upon incubation with sol-
uble CD4, the propensity of V1V2 deleted env to gp120
shedding, and therefore trimer inactivation, was in-
creased. Additionally, we observed faster rates of infect-
ivity decay upon prolonged incubation at 37°C and a
decreased tolerance to temperature increases of V1V2-
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Figure 8 V1V2 function analysis of strains SF162 and P3N. (A) Activity of SF162 and P3N wt and mutant envs was compared in free virus
infection of TZM-bl cells (black) and cell-cell transmission from 293-T cells to A3.01-CCR5 cells (red). Data are normalized to SF162 wt. (B) Comparison
of the same virus panel shown in (A) in free virus infection of TZM-bl cells (black) and cell-cell fusion activity between 293-T cells and TZM-blrhTRIM5α
cells (green). Data are normalized to SF162 wt. (C) Free virus neutralization of env-pvNLLuc pseudoviruses by anti-V3 mAb 1.79 (right) and anti-CD4bs
mAb b6 (left). (D) Assessment of virus temperature stabilities upon long-term incubation of P3N and SF162 wt and ΔV1V2 virus stocks. (E) Assessment
of virus temperature stabilities upon temperature gradient incubation of P3N and SF162 wt and ΔV1V2 virus stocks. (A) to (E): All data shown are mean
and SD from 2 to 3 independent experiments performed in duplicates.
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deleted viruses compared to wt. Both observations, higher
rates of CD4-induced shedding and faster temperature-
induced infectivity loss of V1V2-deleted envs compared
to wt, are in agreement with previous studies showing
high propensities of V1V2-mutant env to negotiate
transitions to low-energy states and trimer inactivation
[26,27]. We further found that the V1V2 domain is
required for shielding of the trimer against neutralizing
antibodies during cell-cell transmission. However, increases
in antibody potency upon V1V2 deletion were less pro-
nounced than in free virus infection, indicating that viruses
with defects in V1V2 that decrease shielding capacity may
benefit from replicating by cell-cell transmission.
A particular emphasis of our study was on studying
the influence of physiologically relevant V1V2 mutations
on the two entry pathways. We probed a comprehensive
panel of V1V2 point mutations and observed similar
patterns as with V1V2 deletion, namely an increased
capacity of the mutants to retain infectivity in cell-cell
transmission while free virus infection was, in several
cases, severely impaired. Of particular interest, we ob-
served two “hot spots” where mutations caused strong
reductions in free virus entry capacity while cell-cell
transmission was retained at significantly higher levels,
suggesting that these regions are particularly important
for ensuring trimer functionality. These regions were
located between residues 156 to 160 and 175 to 180
(Figure 6). The region encompassing residues 156–160
is part of an epitope targeted by antibodies [31-33,48,71],
including the broad and potent antibodies PG9, PG16 and
PGT145. It is tempting to speculate that this region is
preferentially targeted by Abs due to more stringent
structural or sequence constraints compared to the rest of
V1V2. We explored the entry phenotype of V2 position
160 in more detail, as this residue is crucial for the forma-
tion of the epitope of PG9-like antibodies [31,33,34].
Asparagine, as part of an N-linked glycosylation sequon, is
the predominant residue at this position with over 90%
sequence conservation [68]. We found that switching
between asparagine and lysine (N160K) can dramatically
alter both env entry fitness during free virus infection and
neutralization phenotype, in agreement with previous
studies (Figures 7 and 8) [69,72]. Notably though, cell-cell
transmission capacity was less affected than free virus
infection by alterations at position 160, supporting the
notion that neutralization escape variants requiring N160
mutation may be rescued via cell-cell transmission.
Re-introduction of the glycosylation site at position 160 in
strains SF162 and CAP88, which naturally lack a glycosyl-
ation motif at this position, induced a strong increase in
free virus infectivity. Considering the high conservation of
this site across HIV-1 subtypes this may indicate the
importance of this glycosylation for HIV to maintain free
virus spread in natural infection.
The second hot spot we identified encompasses resi-
dues 175 to 180 which have been postulated to mediate
gp120 binding to the α4β7 gut homing receptor. Several
reports suggested that binding to α4β7 fosters efficient
infection of T-cell subsets expressing this receptor
[73,74], while other studies challenged this view [75,76],
currently leaving the physiological importance of α4β7
interaction unresolved. When we analyzed envs contain-
ing mutations of residues that form part of the tripeptide
motif LDI/V at the tip of V2 required for α4β7 binding,
we found that especially mutation of the highly con-
served aspartate at position 180 induced strong reduc-
tions in free virus infectivity, while cell-cell transmission
capacity was maintained at higher levels. This phenotype
was observed both for JR-FL (Figure 1 and 2) and JR-
CSF (Figure 6). A3.01-CCR5 cells used in our study can
express α4β7 [77], whereas TZM-bl cells do not. Thus,
the strong effect we observed upon mutation of residue
180 may not necessarily reflect a lack of binding to this
receptor, but alternatively may indicate the importance of
this highly conserved residue for V2 conformation [78,79].
Recent years have substantiated that cell-cell transmis-
sion is an effective means of virus transmission, at least
in vitro, due to a concentration of virus and receptor
molecules in the donor-target cell contact area, rapid in-
fection which outcompetes spontaneous virus inactivation,
and a high multiplicity of target cell infection [49-57]. The
relevance of cell-cell transmission in vivo remains unre-
solved [80]; however, cell-cell transmission and even cell-
cell fusion were recently demonstrated to occur between
T-cells in HIV-infected humanized mice [81]. Our obser-
vations that viruses carrying envelopes with defects in
V1V2 perform better in cell-cell transmission than in free
virus infection further highlight the potential for the virus
in utilizing the cell-cell transmission pathway. Indeed, our
findings may lend themselves towards an improved under-
standing of virus evolution and spread in vivo. V1V2 is
notable for its high sequence diversity, both within the
swarm of quasispecies of an infected host as wells as
across different HIV subtypes, and may even adopt differ-
ent conformations on the env trimer [67,82,83]. The high
sequence variation and structural plasticity of V1V2 is
likely required to escape antibody neutralization, including
direct escape of V1V2-targeting antibodies and adaptation
of its shielding capacity of distal epitopes such as the V3
loop [3-13]. Given the importance of V1V2 for trimer in-
tegrity and entry, the obvious question is: how can V1V2
functionality be maintained despite the constantly high
sequence variation? Based on our observation that muta-
tions in V1V2 that strongly decrease free virus infectivity
can retain cell-cell transmission capacity, we propose that
cell-cell transmission may constitute a salvage pathway for
the virus (Additional file 13). Upon antibody escape muta-
tions in V1V2 that decrease free virus infectivity, the virus
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may retract to cell-cell transmission until compensatory
mutations, either within or outside V1V2 [84-86], may
emerge that restore the full infection potential. We suggest
that this alternative virus escape pathway should be
considered in future approaches towards HIV treatment
and vaccine design.
Conclusions
The V1V2 domain of the HIV-1 envelope glycoprotein
gp120 combines two essential functions: It is a key regu-
lator of virus infectivity ensuring the functionality of the
envelope trimer and shields the trimer against neutraliz-
ing antibody attack. Rapid antibody escape induced by
mutations in V1V2 highlights the latter activity and is
considered the main driver of the high sequence vari-
ability of the domain. How the high mutation rate in
V1V2 can be tolerated despite the need to maintain
envelope trimer functionality is currently not completely
understood. We hypothesized that preservation of entry
capacity in the face of continuous neutralization escape
mutations will require means for the virus to quickly
adopt compensatory mutations which rescue infectivity.
A prerequisite for the latter is that the initial escape mu-
tants that arise maintain residual entry capacity. In this
study we demonstrate that virus cell-cell transmission,
due to its capacity to excel free virus infectivity, can in-
deed partially rescue infectivity of V1V2 mutant viruses.
Hence, cell-cell transmission may provide an important
salvage pathway for replication of HIV antibody escape
variants until compensatory mutations emerge that
restore free virus infection potential.
Methods
Antibodies and inhibitors
MAbs were kindly provided by: 2F5 [87] and 2G12 [88]
by Dr. Dietmar Katinger, Polymun Scientific, Vienna,
Austria. b6 [89] by Dr. Dennis Burton, The Scripps
Research Institute, La Jolla, USA. 17b [90] by Dr. James
Robinson, Tulane University, New Orleans, USA. 447-
52D [91] was purchased from Polymun Scientific. Ex-
pression plasmids for antibody 1.79 [92] were provided
by Dr. Michel Nussenzweig, The Rockefeller University,
New York, USA. Antibody 1.79 was produced by expres-
sion in 293-F cells followed by purification of the anti-
body by protein G affinity chromatography and size
exclusion chromatography as described [13]. T-20 [93]
was purchased from Roche Pharmaceuticals.
Cells and viruses
293-T cells were obtained from the American Type
Culture Collection (ATCC) and TZM-bl cells [94] from
the NIH AIDS Research and Reference Reagent Program
(NIH ARP). Both cell types were cultivated in DMEM
containing 10% heat inactivated FCS and penicillin/
streptomycin. A3.01-CCR5 T cells were described previ-
ously [58] and were cultivated in RPMI containing 10%
FCS and penicillin/streptomycin. Jurkat T cells [95] were
a gift from Dr. Stuart Neil, King’s College, London, UK
and were cultured in RPMI, 10% FCS and penicillin/
streptomycin. rhTRIM5α-expressing TZM-bl cells were
described previously [58].
All envelope genes used in this study were cloned into
the expression vector pcDNA 3.1 (Invitrogen). Plasmids
encoding the envelopes of strains JR-FL, SF162, NL-43,
RHPA, AC10, REJO, ZM109 and ZM214 were obtained
from the NIH ARP. Envelope clone SF162-P3N [70] was
a gift from Dr. Cecilia Cheng-Mayer, Aaron Diamond
AIDS Research Center, New York, USA. Envelope ZA110
was previously described [13]. Envelope clone CAP88 [96]
was a gift from Dr. Lynn Morris, National Institute for
Communicable Diseases, Johannesburg, South Africa. The
panel of JR-CSF alanine point mutants was kindly pro-
vided Dr. Dennis Burton [65]. For the construction of
V1V2 deleted viruses the restriction sites DraIII (up-
stream) and StuI (downstream) of the V1V2 were utilized
to substitute the original V1V2 domain with a three amino
acid linker sequence DAG as described [13,97]. The same
strategy was employed to produce V1V2 swaps between
envelopes SF162 and P3N. All other mutations were gen-
erated by site directed mutagenesis (QuikChange II kit,
Agilent, Santa Clara, USA) according to the manufacturer
instructions.
Clinical specimen
Plasma samples used for neutralization studies were
obtained from 19 adult individuals with chronic HIV-1
infection (subtypes A, B, C, AE and AG, > 6 months
infected) enrolled in the Zurich center of the Swiss HIV
Cohort Study [98] and the Zurich Primary HIV-infection
(ZPHI) study [99]. The plasma sample from patient
ZA110 used in Figure 5, a participant of the ZPHI study,
was collected 61 weeks before the time point at which
the probed env was isolated [13].
Ethics statement
All clinical specimens were derived from adult partici-
pants enrolled in the Zurich center of the Swiss HIV
Cohort Study [98] or the ZPHI study [99]. All studies
were approved by the ethics committee of the University
Hospital Zurich and written informed consent was
obtained from all individuals.
Sequencing
All envelope sequence data are recorded based on HXB2
numbering. Sequencing of envelope genes was performed
using in-house Sanger sequencing.
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Preparation of HIV-1 virus stocks
To prepare pseudovirus stocks 293-T cells were trans-
fected with the respective viral backbones and the enve-
lope of choice as described [100]. 48 h post-transfection,
virus containing supernatants were harvested and infect-
ivity was determined on TZM-bl reporter cells as de-
scribed [100]. The following virus constructs were used:
The GFP reporter HIV pseudotyping vector pNLGFP-
AM ([58]; denoted env-pvNLGFP) was co-transfected with
env encoding plasmids to compare free virus infectivity
and cell-fusion (Figures 2 and 3). The Luciferase reporter
HIV pseudotyping vector pNLLuc-AM ([13]; denoted
env-pvNLLuc) was co-transfected with env encoding plas-
mids to probe free virus neutralization activity (Figures 5
and 8) and free virus stability and gp120/p24 content
(Figure 4). The lentiviral packaging vector pCMV-dR8.91
([101]; gift from Dr. Didier Trono, EPFL Lausanne,
Switzerland) was co-transfected with an env encoding plas-
mid and the inGLuc reporter construct pUCHR-inGLuc
([56,62], kindly provided by Dr. Walther Mothes and
Dr. Gisela Heidecker, see section on cell-cell trans-
mission below for details). The obtained pseudoviruses
(encoded env-pvinGLuc) were used for comparison of free
virus and cell-cell transmission (Figures 1, 2, 3, 5, 6, 7, 8).
To monitor cell-cell transmission in a T-cell to T-cell
setting, we generated replication competent (rc) viruses
containing the envelopes of JR-FL and ZA110 with the
indicated mutations in the TN6 NL vector, a replication-
competent viral backbone engineered from strain NL4-3
(kindly provided by Dr. M. Dittmar, Queen Mary Univer-
sity of London, UK) as described [102]. These env-TN6
encoding plasmids were co-transfected with the inGLuc
reporter plasmid on Jurkat T cells (encoded env-rc
TN6inGLuc) and used in free virus and cell-cell transmis-
sion experiments (Figures 2 and 3). Infectivity of env-
pvNLLuc and env-pvNLGFP viruses on TZM-bl cells was
quantified by measuring firefly luciferase activity using
firefly luciferase substrate (Promega, Madison Wisconsin,
USA). Infectivity of env-pvinGLuc and env-rc TN6inGLuc on
target cells (TZM-bl and A3.01-CCR5) was quantified by
measuring Gaussia luciferase activity using the Renilla-
Glo Luciferase Assay System (Promega AG, Madison,
USA).
Comparing HIV-1 free virus infectivity and cell-cell
transmission capacity
We employed the recently described inGLuc reporter
system [56,62] to assess HIV cell-cell transmission. This
setup employs a reporter plasmid (pUCHR-inGLuc) con-
taining Gaussia luciferase in reverse orientation, inter-
rupted by an intron in forward orientation. Splicing of
the intron in plasmid-transfected HIV donor cells, pack-
aging of the spliced RNA into virions followed by infec-
tion, reverse transcription and integration in a target cell
leads to Gaussia luciferase reporter gene expression.
Hence, no signal is induced in plasmid-transfected cells
or from cell fusion ([56,62], Figure 1 and data not shown).
Virus infectivity in this system is sensitive to both protease
and RT inhibitors as expected for cell-cell transmission
([103] and Figure 1). To assess cell-cell transmission in
absence of free virus transmission we restricted free virus
infectivity by omission of DEAE-dextran (diethylami-
noethyl-dextran; Amersham Biosciences, Fairfield, Con-
necticut, USA) in the infection media [58].
To directly compare free virus infectivity and cell-cell
transmission, 293-T cells (2 wells of a 12-well plate per
env; 100.000 293-T cells per well seeded one day before
transfection) were transfected with env expression plasmid,
inGLuc plasmid and the lentiviral packaging vector
pCMV-dR8.91 (0.2 μg, 1.2 μg and 0.6 μg per well, re-
spectively) using polyethyleneimine (PEI) as transfection
reagent. 6 h post-transfection, one well for each env was
processed for free virus infectivity, while the other well
was used to probe cell-cell transmission.
Free virus infectivity
To obtain virus supernatant for estimating free virus in-
fectivity, the supernatant of a transfected 12 well was as-
pired 6 h post transfection and replaced with 1 ml fresh
complete DMEM. 48 h post-transfection, the virus-
containing supernatant was harvested, cleared by centri-
fugation (300 g, 3’) and stored at −80°C. Subsequently
free virus infectivity was determined by adding serial di-
lutions of virus stocks, starting with a maximal input of
100 μl, to TZM-bl or A3.01-CCR5 cells in 96-well plates
in medium containing 10 μg/ml of DEAE-dextran and
measuring Gaussia luciferase activity 60 h post-infection.
Cell-cell transmission
To measure cell-cell transmission, the supernatant from
transfected 293-T cells was aspired 6 h post transfection
and the cells were resuspended in 1 ml fresh complete
RPMI medium containing no DEAE (yielding approxi-
mately 15.000 cells per 100 μl). Subsequently, cells were
re-seeded in 96-well plates (100 μl per well), and per
well 50.000 A3.01-CCR5 cells were added in 100 μl
RPMI medium. After 60 h incubation at 37°C Gaussia
luciferase production was measured to determine target
cell infection.
Assessing HIV-1 T-cell to T-cell transmission
In order to probe virus transmission from T-cells to T-
cells we seeded Jurkat T-cells in 12-well plates at 500.000
cells per well in complete RPMI medium. Cells were
transfected with infectious molecular clones of HIV (TN6
NL vector encoding different env) and the inGLuc re-
porter plasmid (2 μg and 0.5 μg per well, respectively)
using Jurkat TransIT (Mirus Bio LLC, Madison, USA) as
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transfection reagent. 6 h post-transfection, the transfection
medium was removed and we either (i) added 1 ml fresh
complete RPMI, or (ii) resuspended cells in 1 ml RPMI,
transferred 100 μl to 96-well plates, and added 50.000
A3.01 cells in 100 μl fresh complete RPMI. From the wells
containing only Jurkat cells, the cell-free supernatant was
harvested 48 h after the medium change and the free
virus titer was determined on TZM-bl cells by Gaussia
luciferase read-out as described above. From the wells
containing the co-culture of Jurkat and A3.01 cells, a
Gaussia luciferase read-out was performed 60 h after
starting the co-culture.
Comparing HIV-1 free virus infectivity and cell-cell fusion
capacity
Free virus infectivity and cell-cell fusion activity was
probed using 293-T cells producing env pseudotyped re-
porter virus (env-pvNLGFP) on TZM-bl target cells. 293-T
cells were seeded in 12-well plates 1 day before transfec-
tion (100.000 cells per well in 1 ml complete DMEM). For
each env, two wells of 293-T cells were transfected with
env-encoding plasmid and reporter vector pNLGFP-AM
(0.5 μg plus 1.5 μg per well, respectively) using PEI as
transfection reagent. 6 h post-transfection, one well for
each env was processed for free virus infectivity, while the
other well was used to probe cell-cell fusion.
Free virus infectivity
For free virus infectivity, the transfection supernatant
was aspired 6 h post transfection and replaced with 1 ml
fresh complete DMEM. 48 h post-transfection, the virus-
containing supernatant was harvested, cleared by centrifu-
gation (300 g, 3’) and TZM-bl cells were infected with
serial dilutions of the virus supernatant in medium con-
taining DEAE-dextran. 48 h post infection firefly luciferase
activity in the TZM-bl cells was measured.
Cell-cell fusion
Envelope fusogenicity was assessed by Tat driven induc-
tion of firefly luciferase in TZM-blrh-TRIM5α targets cells
upon co-culturing with 293-T cells transfected with env
and the viral backbone plasmid pNLGFP-AM. In TZM-
blrh-TRIM5α cells free virus infectivity is potently restricted
through expression of rhTRIM5α [58,104]. Co-culturing
of env pseudovirus-expressing 293-T cells with TZM-
blrh-TRIM5α cells leads to a rapid induction of the LTR
driven luciferase reporter in the TZM-bl cells due to Tat
transfer from transfected donor 293-T cells during fusion.
To measure cell-cell fusion, the supernatant of a 12-well
containing pNL-GFP AM and env transfected 293-T cells
was aspired after 6 h, and the cells were resuspended in
1 ml fresh DMEM (yielding approximately 15.000 cells
per 100 μl). Cells were then distributed in 96-well plates
(100 μl per well), and per well 15.000 TZM-blrh-TRIM5α
cells in 100 μl complete DMEM were added. After 24 h
incubation at 37°C production of firefly luciferase was
measured.
Assessment of gp120 shedding
To probe propensity of different envs to CD4 induced
shedding of gp120 from trimers, 293-T cells were seeded
in 12-well plates (100.000 cells per well in 1 ml complete
DMEM). 24 h later, cells were transfected with env-
encoding plasmids and a rev-encoding plasmid (1.6 μg
plus 0.4 μg per well, respectively). 8 h post-transfection
the medium was replaced, and 48 h post-transfection
the medium was aspired and cells resuspended in FACS
buffer (PBS, 2 mM EDTA, 2% FCS). The cells were
transferred to a 96-well plate and treated with sCD4
(10 μg/ml in FACS buffer) or mock (FACS buffer) for
30’ at 37°C. Subsequently, the cells were washed twice
with FACS buffer and envelope on the cell surface was
detected with biotinylated mAb 2G12 (5 μg/ml in FACS
buffer) and Streptavidin-APC (BioLegend, San Diego,
USA; 1:400 in FACS buffer) followed by analysis of the
cells on a CyAN ADP flow cytometer (Beckman Coulter,
Brea, USA). Percent shedding was calculated as the
mean fluorescence intensity (MFI) of the sCD4-treated
cells divided by the MFI of the mock-treated cells.
Quantification of gp120 and p24 content of pseudotype
virus stocks
To determine gp120 and p24 content of virus prepara-
tions, env-pvNLLuc viruses were produced in 293-T cells
(T25 flasks; 750.000 cells in 5 ml medium, seeded 24 h
pre-transfection). The medium was changed 12 h post-
transfection and virus-containing supernatants harvested
48 h post-transfection. The supernatants were cleared by
low speed centrifugation (300 g, 3’), then ultracentri-
fuged (SW28 rotor, 2 h, 28.000 rpm, 4°C), the super-
natant removed and viral pellets resuspended in 0.3 ml
cold PBS and stored at −80°C. Virion associated p24 and
gp120 antigens were quantified by ELISA as previously
described [13]. Briefly, virus preparations were dissolved
in 1% Empigen (Fluka Analytical, Buchs, Switzerland)
and dilutions of each sample probed for gp120 and p24.
Gp120 was captured on anti-gp120 D7324 (Aalto Bior-
eagents, Dublin, Ireland) coated immunosorbent plates
and detected with biotinylated CD4-IgG2 and Streptavidin-
coupled Alkaline Phosphatase (GE Healthcare, Chalfont St
Giles, UK). P24 was captured on anti-gp120 D7320 (Aalto
Bioreagents, Dublin, Ireland) coated plated and detected
using Alkaline Phosphatase-coupled antibody BC1071-AP
(Aalto Bioreagents, Dublin, Ireland).
Assessment of virus temperature decay
We employed two different experimental setups to
probe temperature-induced virus infectivity loss. In the
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first assay, 250 μl aliquots of wt and V1V2-deleted
env-pvNLLuc virus stocks were incubated at 37°C for up
to 80 h. At defined time points, the titer of an incubated
sample was determined by titration on TZM-bL cells
and set in relation to the titer of a freshly thawed aliquot
to retrieve the relative loss in infectivity over time of in-
cubation at 37°C. For the second assay, virus stocks were
transferred to 96-well PCR plates (125 μl per well) and
incubated for 5 h over a temperature gradient ranging
from 25°C to 45°C in 2.5° steps in a Biometra T-gradient
96-well PCR block (Biometra GmbH, Göttingen, Germany).
Following incubation, the samples were titrated on TZM-
bl cells and the infectivity of each sample was normalized
to the sample incubated at 25°C (100% infectivity), yielding
relative infectivity curves as a function of incubation
temperature.
Neutralization of cell-free env-pseudotyped virus
The neutralization activity of mAbs and patient plasma
against cell-free env-pvNLLuc viruses was evaluated on
TZM-bl cells as described [100]. Virus input was chosen
to yield virus infectivity corresponding to a luciferase
activity of 5000 to 20.000 RLU in absence of inhibitors.
The antibody concentrations or reciprocal plasma titers
causing 50% reduction in viral infectivity (inhibitory
concentration IC50 or neutralization titer NT50) were
calculated by fitting pooled data from two to three inde-
pendent experiments to sigmoidal dose response curves
(variable slope) using GraphPad Prism. If 50% inhibition
was not achieved at the highest or lowest antibody or
plasma concentration, a greater-than or less-than value
was recorded.
Neutralization assay during cell-cell fusion and cell-cell
transmission of env-pseudotyped virus
To assess neutralization during cell-cell fusion, 293-T cells
transfected with plasmids encoding env-pvNLGFP were
re-seeded 6 h post transfection at 10.000 cells in 100 μl
DMEM medium per well of 96 well plates and serial dilu-
tions of inhibitors (50 μl per well) were added to the cells.
Following a 1 h incubation at 37°C, TZM-blrhTRIM5α target
cells were added to the 293-T cell – inhibitor mix (10.000
TZM-blrhTRIM5α cells per well in 50 μl DMEM). 24 h post
co-culture start, firefly luciferase activity was quantified as
described. To assess neutralization during cell-cell trans-
mission, we used the same assay strategy with the following
adaptations. 293-T cells were transfected with plasmids
encoding env-pvinGLuc and later co-cultured with 50.000
A3.01-CCR5 target cells per well in 96-well plates. Gaussia
luciferase activity in the culture supernatant was quanti-
fied 60 h after co-culture. Neutralization assay data from
both setups were processed in GraphPad Prism as described
above for free virus neutralization.
Statistical analysis
All correlations were performed in GraphPad Prism
according to Pearson. Analyses for statistical significance
were performed with GraphPad Prism using either
paired t-tests (Figure 4B and C, with the exact p-values
indicated) or multiple unpaired t-tests (Figures 2, 3, 6, 7)
with statistical significance defined by alpha = 0.05.
Additional files
Additional file 1: Assay setups to study free virus infection and
cell-cell transmission. (A) Overview of the assay formats used to dissect
free virus infection and cell-cell transmission. (B) Experimental assay
scheme: To study and quantitatively compare HIV free virus infection and
cell-cell transmission virus donor cells (either 293-T cells or Jurkat T cells)
were transfected with HIV encoding plasmids and the inGLuc reporter
plasmid. Transfection was performed in 12-well plates, with two wells per
env. Six hours post-transfection, one well was processed for cell-cell
transmission, and one well for free virus infection: (i) To assess cell-cell
transmission, the donor cells were resuspended in 1 ml medium and
re-seeded in 100 μl volume in 96-well plates, giving approximately 15.000
293-T cells or 50.000 Jurkat cells per well. Then, 50.000 A3.01-CCR5 T-cells
in 100 μl medium were added and the co-culture was incubated at 37°C
for 60 h. To restrict free virus infection of the target cells, DEAE dextran
was omitted from the culture medium. The extent of cell-cell transmission
from the donor to the A3.01-CCR5 target cells was quantified by Gaussia
luciferase read-out. (ii) To assess free virus infection, the virus-containing
supernatant of the second 12-well of donor cells was harvested and
subsequently titrated on either A3.01-CCR5 or TZM-bl target cells in 96-well
plates. Assay conditions and free virus input (starting at 100 μl) were chosen
to reflect cell-cell transmission co-culture conditions. The extent of free virus
infectivity of the target cells was quantified by Gaussia luciferase read-out.
Additional file 2: Normalization approach for free virus infection
and cell-cell transmission data. (A) In both free virus infection and cell-
cell transmission setups Gaussia luciferase (GLuc) activity is measured to
monitor infection. Raw values are obtained as Relative Light Units (RLU). Let
us assume that a wt and a mutant env have RLU values in free virus
infection of a and b, respectively. Similarly, in cell-cell transmission these
envs will have RLU values of c and d, respectively. (B) The relative infectivity
of the mutant env to the wt env in free virus infection is then given by a
divided by b, multiplied by 100 to obtain the value in percent of wt infectivity.
Likewise, the relative infectivity of the mutant env in cell-cell transmission is
determined. (C) To obtain a measure of the relative efficacy of the mutant
env in the two transmission pathways, we divide the relative cell-cell
transmission activity by the relative free virus infection capacity. Thus, a value
of 1 will indicate equal free virus and cell-cell transmission capacities, a value
below 1 indicates better free virus infectivity than cell-cell transmission
capacity, and a value greater than 1 indicates better cell-cell transmission
capacity than free virus infection capacity.
Additional file 3: Gaussia luciferase activity of V1V2-deleted and wt
envs in free virus infection and cell-cell transmission.
Additional file 4: Correlation analyses of V1V2-deleted env entry
and trimer stability characteristics. (A) to (G): All correlations were
performed in GraphPad PRISM according to Pearson. (A) Correlation
analysis of ΔV1V2 env free virus entry fitness and fusion fitness. Data are
derived from Figure 3B and C. (B) Correlation analysis of ΔV1V2 env free
virus entry fitness and virus half-life. Data are derived from Figure 3B and 4B.
(C) Correlation analysis of ΔV1V2 env free virus entry fitness and temperature
sensitivity. Data are derived from Figure 3B and 4C. (D) Correlation analysis
of ΔV1V2 env fusion fitness and virus half-life. Data are derived from
Figure 3C and 4B. (E) Correlation analysis of ΔV1V2 env fusion fitness and
temperature sensitivity. Data are derived from Figure 3C and 4C.
(F) Correlation analysis of ΔV1V2 env cell-cell transmission fitness and virus
half-life. Data are derived from Figure 3B and 4B. (G) Correlation analysis of
ΔV1V2 env cell-cell transmission fitness and temperature sensitivity. Data are
derived from Figure 3B and 4C.
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Additional file 5: JR-FL wt and ΔV1V2 env expression on
transfected 293-T cells and on virions. (A) Example of a flow
cytometry histogram of JR-FL wt and ΔV1V2 expressing 293-T cells. Env
expression on 293-T cells was detected with biotinylated mAb 2G12 and
streptavidin-APC. Mock-transfected cells subjected to the same staining
protocol are shown in grey. (B) The mean fluorescence intensities (MFI)
of 293-T cell populations expressing wt and V1V2-deleted envs and
stained with mAb 2G12, including strains JR-FL, NL4-3 and SF162, were
calculated. Mean and SD of two independent experiments are shown.
(C) To derive estimates of average virion gp120 content, pseudotype
virus stocks of wt and V1V2-deleted envs of the indicated strains were
purified by ultracentrifugation. Subsequently, the purified virus was
subjected to gp120 and p24 ELISA. Shown here are the relative gp120
and p24 contents of the V1V2-deleted strains, normalized to each
matching wt strain. The p24 content of V1V2-deleted virus stocks was in
the same range as the wt stocks, indicating that V1V2 deletion did not
affect overall levels of pseudoparticle production. Concerning gp120
content, we observed marked reductions in gp120 content for strains
ZM109 ΔV1V2 (approximately 10% of wt gp120 content), which was not
functional as free virus, and JR-FL ΔV1V2 (approximately 40% of wt
gp120 content). All other strains showed gp120 levels at ≥ 80% of wt.
Symbols depict mean values derived from 3 independent experiments
with ELISAs performed in duplicates.
Additional file 6: Long-term incubation infectivity decay curves of
wt and V1V2-deleted virions. Long-term incubation infectivity decay
curves for wt virions (black) and V1V2-deleted virions (red). The data
shown here were employed to calculate virus half-life as depicted in
Figure 4B. Data points are mean and SD from two to three independent
experiments performed in duplicates.
Additional file 7: Temperature gradient infectivity decay curves of
wt and V1V2-deleted virions. Temperature gradient infectivity decay
curves for wt virions (black) and V1V2-deleted virions (red). The data
shown here were employed to calculate the temperature at which 50%
virus infectivity remain as depicted in Figure 4C. Data points are mean
and SD from two to three independent experiments performed in
duplicates.
Additional file 8: Correlation analysis of virus half-life and
temperature tolerance. Correlation analyses (according to Pearson)
between virus half-life (Figure 4B and Additional file 6) and temperature
tolerance (Figure 4C and Additional file 7) are shown for wt virions (top)
and V1V2-deleted virions (bottom).
Additional file 9: Correlation and cell-cell fusion analysis of the
JR-CSF env mutant panel. (A) Correlation analysis (according to
Pearson) of the data shown in Figure 6. Mutants with high discrepancy
between free virus infection and cell-cell transmission capacities are
marked in red. (B) Correlation analysis upon exclusion of mutants marked
red in (A). (C) Comparison of free virus infectivity (black) and cell-cell
fusion capacity (green) of the JR-CSF mutant panel. Fusion activity
followed the same trend as seen for cell-cell transmission (Figure 6) with
several mutants losing free virus infection potential but retaining cell-cell
fusion capacity. Values of relative efficacy of cell-cell fusion versus free
virus infection are shown below the bars; a star indicates whether this
difference is statistically significant as probed by multiple unpaired t-tests
with alpha = 0.05. Data shown are mean and SD from 3 independent
experiments performed in duplicates.
Additional file 10: Cell-cell fusion analysis of the env N160K/K160N
mutant panel. Analysis of free virus infectivity (black) and cell-cell
fusion capacity (green) of the env N160K/K160N mutant panel. We
observed similar trends as shown for free virus infection and cell-cell
transmission in Figure 7. Envs with the N160K mutation lost in free
virus infectivity to varying extent, while cell-cell fusion activity was
largely retained. SF162 and Cap88 profited from the K160N mutation
and showed enhanced free virus infectivity, while cell-cell fusion
capacity was only moderately increased. Values of relative efficacy of
cell-cell fusion versus free virus infection are shown below the bars; a
star indicates whether this difference is statistically significant as
probed by multiple unpaired t-tests with alpha = 0.05. Data shown are
mean and SD from 3 independent experiments performed in
duplicates.
Additional file 11: Sequence alignment of SF162 and P3N envs.
Sequences were derived from in-house sequencing of the respective env
clones. The V1V2 domain is boxed in red. Residue numbering is based on
SF162. In addition to sequence changes in V1V2, several additional
residue changes in both gp120 and gp41 are apparent in P3N compared
to the parental SF162 env.
Additional file 12: Correlation analysis of neutralization sensitivity
and entry fitness of the SF162/P3N env panel. Correlation analysis
(according to Pearson) of IC50s for mAbs b6 and 1.79 and the free virus
entry fitness of the 8 envs of the SF162/P3N V1V2 swap and point
mutant panel (neutralization and free virus entry data are shown in
Figure 8) highlights considerable correlation between free virus entry
capacity and neutralization resistance.
Additional file 13: A putative model for V1V2 function in free virus
infection and cell-cell transmission. (A) In a situation where no
neutralizing Abs (black) are present, HIV-1 efficiently infects target cells
both as free virus and via cell-cell transmission. (B) If neutralizing antibodies
(blue) develop that bind and neutralize the contemporaneous virus trimer,
free virus infection will be neutralized. However cell-cell transmission, being
more resistant to antibody neutralization, may persist at lower levels.
(C) Eventually, virus escape mutations to the neutralizing antibodies will
emerge. These escape mutations may be located in V1V2 (indicated as red
V1V2 loops). The escape mutations may interfere with V1V2 function thereby
reducing free virus entry capacity (dashed arrow to target cell). However, the
mutations may be better tolerated in the context of cell-cell transmission,
resulting in preferential virus spread via this transmission pathway (bottom).
(D) After some rounds of virus replication via cell-cell transmission,
mutations in gp120/gp41 may emerge (indicated in yellow) which
compensate the defects in V1V2, thereby restoring trimer functionality and
free virus infectivity while maintaining antibody resistance.
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